The American College of Cardiology, American Heart Association and Heart Failure Society of America worked together on the updated document, adding three new performance measures and six new quality measures. They did not remove a single recommendation from the previous document published in 2020.

The J Valve from JC Medical was linked to positive outcomes and “excellent” hemodynamic data after 30 days in an early feasibility study published in JACC: Cardiovascular Interventions. Researchers noted that the valve showed potential in patients with large aortic annuli, which represents an "unmet critical need" at this stage. 

The new expert consensus decision pathway replaces a similar document from 2019 and is to be used in conjunction with heart failure guidelines published in 2022 by the ACC, American Heart Association and Heart Failure Society of America.

The Danish pharmaceutical company said it will resubmit its application in 2025 to have Wegovy approved for use in heart failure patients.

The new device from Huxley Medical offers care teams a way to monitor patients for signs of sleep apnea while also keeping a close eye on their heart health. 

Treating severe MR with the popular device does not appear to increase a patient's risk of stroke or transient ischemic attack. When patients present with AFib, however, care teams may want to make certain adjustments to optimize outcomes. 

The study's findings indicate that obtaining a prostate MRI at the time of a patient's initial diagnosis may provide important insight into how cancer will progress over time.

Medtronic and Abbott are often seen as rivals in a competitive marketplace, but the two companies are collaborating with a simple goal in mind: improving patient access to high-quality CGM devices.